Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells

Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis and promoting tumor healing in MDA-MB231 xenografts and the 4T1-12B syngeneic breast cancer metastasis model. Mechanistic studies in MDA-MB231  cells revealed that alkylation upregulates inflammatory genes/proteins such as COX-2, IL8, CXCL2 and MMP1 in a MEK1/2-ERK1/2-dependent manner.

Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Alfeu Zanotto-Filho, Subapriya Rajamanickam, Eva Loranc, V. Pragathi Masamsetti, Aparna Gorthi, July Carolina Romero, Sonal Tonapi, Rosangela Mayer Gon çalves, Robert L. Reddick, Raymond Benavides, John Kuhn, Yidong Chen, Alexander J.R. Bishop Tags: Original Articles Source Type: research